Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response.
about
Insight to drug delivery aspects for colorectal cancerMyeloid-derived suppressor cells and anti-tumor T cells: a complex relationshipSuppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cellsRepression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.A critical role for virus-specific CD8(+) CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice.IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cellsProtocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapyTh inducing POZ-Kruppel Factor (ThPOK) is a key regulator of the immune response since the early steps of colorectal carcinogenesis.Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model.Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer.Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunizationRadiation-induced CXCL16 release by breast cancer cells attracts effector T cells.Signaling defects in anti-tumor T cellsSystemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapyTissue vaccines for cancer.The tumor microenvironment: part 1.Lipid A-mediated tolerance and cancer therapy.Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation.Induction of antigen-specific effector-phase tolerance following vaccination against a previously ignored B-cell lymphoma.Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy.Myeloid suppressor cells regulate the adaptive immune response to cancer.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Advances and Prospects in Cancer Immunotherapy
P2860
Q26774682-59F2714F-DCC5-4A27-BAA9-7C3ABD42ECD5Q27000087-3A0812A1-AAD0-4F53-90B9-093849ABA10DQ30418212-E1D38257-BAF0-4D8F-AEB2-A8FD2A430A12Q33288897-54AAA6A6-68F5-4625-957B-B979DC528B7CQ33857396-441DE237-D442-4010-8E5B-AFA56766C0A3Q34095907-DBC74D55-6149-4CF4-B674-8268EBFBE888Q34261705-74474832-7E1D-4978-9A8E-CF71171ADE9EQ34556927-CE17D136-183F-402C-A308-BB8E2487BC2CQ34563178-A656F95C-2F9A-43BA-B64C-75D67417AF03Q34700365-37E019C7-A279-4E83-BAC0-9AE289D3A9AAQ35169807-B83B0F9B-1305-452E-9B15-EBEC5713D461Q36863949-54C6AE51-8B61-4295-9F11-ED008BD7053CQ36983211-FDC2FD7C-7DAC-46A2-98FE-8AB50F264415Q37063739-96DD184D-CD16-4EC5-B874-875BBD4320DBQ37087603-E122E167-A039-4DCD-89B2-44BADA70B87FQ37123446-5335800D-63E0-4F32-9CBA-9BFA5E4EBD5FQ37952794-468F0CBA-97FB-4A71-95A1-0270593451A4Q38496963-421765B1-BD9A-466B-9961-13D58CAE010CQ38845195-605F61F2-DEF4-4AD9-B939-BC8B8A989368Q39478425-D12078A4-F83D-4BFB-89EB-B7C0A454D592Q39631497-66D99F63-A28D-4CF7-A454-1FFF720BCBB9Q39722061-2C098E0F-DDB8-436D-B1F3-FC8290E594AFQ39894616-F3B6C1CF-72BE-45E5-A39C-74BEB61A0877Q41764893-14A64D23-FDF0-4A66-A4BF-EA2CC81FF86BQ43259754-C7A0694A-1060-4592-A16A-A2F898612170Q49830211-2F52F8D6-44AD-478A-8CCA-7850E48DF608Q59072375-C2A4B6E9-CD1F-4C92-B1A0-7C5F2E5B09EE
P2860
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Effector-phase tolerance: anot ...... pes antitumor immune response.
@ast
Effector-phase tolerance: anot ...... pes antitumor immune response.
@en
type
label
Effector-phase tolerance: anot ...... pes antitumor immune response.
@ast
Effector-phase tolerance: anot ...... pes antitumor immune response.
@en
prefLabel
Effector-phase tolerance: anot ...... pes antitumor immune response.
@ast
Effector-phase tolerance: anot ...... pes antitumor immune response.
@en
P356
P1476
Effector-phase tolerance: anot ...... pes antitumor immune response.
@en
P2093
Alan B Frey
Ngozi Monu
P304
P356
10.1189/JLB.1105628
P577
2006-01-13T00:00:00Z